Go to the profile of Aptahem

Aptahem

 
  • Sweden

About Aptahem

Aptahem AB is a Swedish-based biotechnology company that develops innovative aptamer-based drugs targeting inflammation and coagulation for the treatment of life-threatening conditions. The portfolio under development consists of multifunctional aptamer (synthetic constructed nucleic acid polymers) drug candidates with anti-coagulant, immunostimulant and anti-inflammatory properties. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by the severe inflammatory response that leads to organ and tissue damage in sepsis patients. The multi-functional profile of Apta-1 has shown to improve the survival of animals in a dose dependent manner in a lethal sepsis model in an unprecedented way. Aptahem is also investigating a second candidate, Apta-2, for the treatment of inflammatory diseases. The company holds patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.

Therapeutic Areas

Cardiovascular Central Nervous System Dermatology Infectious Inflammation Metabolic Ophthalmics

Technologies

Antimicrobial Diagnostics Drug delivery Regenerative medicine

Company Type

Biotechnology – R&D services

State of Ownership

Private

Sponsorship Group

Networker

Topics

Editions participated in:

June 2018